Artelo Biosciences (NASDAQ:ARTL) Lowered to “Hold” Rating by D Boral Capital

D Boral Capital cut shares of Artelo Biosciences (NASDAQ:ARTL) from a strong-buy rating to a hold rating in a research report released on Wednesday morning,Zacks.com reports.

Several other research analysts have also weighed in on ARTL. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Artelo Biosciences in a research report on Friday, June 6th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Artelo Biosciences in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $33.00.

Artelo Biosciences Trading Up 1.6%

ARTL stock opened at $7.20 on Wednesday. The stock has a 50-day moving average price of $6.07 and a 200-day moving average price of $6.36. Artelo Biosciences has a 1-year low of $4.92 and a 1-year high of $9.30. The firm has a market cap of $23.61 million, a PE ratio of -2.51 and a beta of 1.03.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($4.32) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($3.54). On average, analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.